Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TheraCLEC-Total dose ranging in CF with EPI
NCT00095732Phase 2Completed
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Jun 2004
- Primary completion
- Mar 2005
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liprotamase in exocrine pancreatic insufficiency (EPI) (3 arms), sponsored by Anthera Pharmaceuticals, Inc. Primary endpoint: Coefficient of Fat Absorption at 19 days. Started Jun 2004; status: completed.
02
Drugs
liprotamase
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT00095732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095732.